Tumor stage classification with a survival survey during detection time is the most crucial part of cancer treatment. The survivability period is directly associated with the early detection of the stage. This study developed a hybrid model to accurately classify the tumor (T) stages with the survivability analysis. The study aims to provide an explainable Artificial Intelligence framework (such as SHAP, and SHAPASH), through which the trustability and interpretability of the proposed model can increase. Along with the XAI, this hybrid approach uses two statistical models, ANOVA and LASSO with the standard TNM (tumor, node, metastasis) method for the T-stage classification. Afterward, the survivability analysis for each T stage is shown by the Kaplan–Meier (KM) method, proportion hazard ratio (Cox). Where KM is used to represent the survivability of individual tumor stages in months and the Cox regression shows the risk factors of the events. Initially, the proposed model was examined on a full dataset that contained malignant and benign data for evaluating the performance of the model, therefore stage classification for T1, T2, and T3 performs for malignant data. The K-fold and repeated-stratified K-fold cross-validation are used to measure the accuracy of the whole dataset for lung and breast cancer. For lung cancer, maximum accuracy was attained by MLP–97.64 in K-fold cross-validation. In breast cancer maximum accuracy achieved by GPC-99.57 in repeated-stratified K-fold cross validation. The results of both datasets are compared with the state-of-the-art models. The study contributed by representing the significance of individual features for tumor staging using the advanced approach of XAI, the SHAPASH interface. The accuracy of the T1, T2, and T3 stages based on malignant data was demonstrated with various classifier models with cross-validation. Finally, it is expected that executing that approach will improve patient outcomes. By using, advanced artificial intelligence and data-driven insights, this study contributes notably to the current actions for tumor stage classification with survivorship analysis.